In four Phase III clinical trials, the adverse-event profile of ZAVICEFTA was similar to that seen with either best-available therapy, doripenem or meropenem.1–4
Overall rates of any AE were low in ZAVICEFTA and comparator arms1–4
Rates of all other categories of AEs were low and balanced across treatment arms1–4
Most common (≥ 5%) AEs for ZAVICEFTA were positive Direct Coombs test, nausea and
No requirement for routine monitoring and a low potential for drug–drug interations5
Nausea and diarrhoea were usually
mild or moderate in intensity1–5
An overall safety profile consistent with that of ceftazidime alone1–5
Incidence of very common (≥1/10) and common (≥1/100 and <1/10) adverse drug reactions occurring in patients receiving ZAVICEFTA (ceftazidime–avibactam) during Phase II and III clinical trials:5
Very common and common adverse reactions by system organ class
No requirement for routine monitoring and a low potential for drug–drug interactions5
In vitro drug combination studies with ZAVICEFTA have demonstrated neither synergy nor antagonism with the following drugs: metronidazole, tobramycin, levofloxacin, vancomycin, linezolid, colistin and tigecycline.
ZAVICEFTA has the following contraindications:5
ZAVICEFTA has some special warnings and precautions for use5
Learn more about ZAVICEFTA’s dosing in adult and paediatric patients.
AE, adverse event; DAGT, direct antiglobulin test; DDI, drug–drug interaction; OAT, organic anion transporter.
Pfizer AS, Org.nr 915 213 596
Postadresse: Postboks 3, 1324 Lysaker
Besøksadresse: Drammensveien 288, 0283 Oslo
Tlf.: +47 67 52 61 00
PP-BCP-NOR-0001 juni 2023
Copyright © 2023 Pfizer AS. Innholdet er rettighetsbeskyttet.
Dette nettstedet er kun for helsepersonell.
Jeg bekrefter at jeg er helsepersonell som definert i legemiddelforskriften §13-1.
Ved å velge "nei" vil du komme til Pfizer.no som er åpen for allmenheten.